Publications by authors named "G Pelagalli"
Article Synopsis
- The study investigated how acute ischemic stroke (AIS) affects patients with nonvalvular atrial fibrillation (NVAF) who are using oral anticoagulants (OA), specifically comparing direct oral anticoagulants (DOAC) and vitamin K antagonists (VKA).
- A total of 169 patients were examined, revealing that those on VKA had higher in-hospital mortality rates and poor outcomes 90 days after the stroke compared to DOAC users.
- The researchers found that switching anticoagulants did not impact stroke recurrence rates, suggesting that further extensive research is needed to optimize treatment for AIS in OA patients.
Background: Analysis of autopsy tissues obtained from patients who died from COVID-19 showed kidney tropism for SARS-COV-2, with COVID-19-related renal dysfunction representing an overlooked problem even in patients lacking previous history of chronic kidney disease. This study aimed to corroborate in a substantial sample of consecutive acutely ill COVID-19 hospitalized patients the efficacy of estimated GFR (eGFR), assessed at hospital admission, to identify acute renal function derangement and the predictive role of its association with in-hospital death and need for mechanical ventilation and admission to intensive care unit (ICU).
Methods: We retrospectively analyzed charts of 764 patients firstly admitted to regular medical wards (Division of Internal Medicine) for symptomatic COVID-19 between March 6th and May 30th, 2020 and between October 1st, 2020 and March 15th, 2021.
Article Synopsis
- The study investigates predictive factors for hemorrhagic transformation (HT) in acute ischemic stroke patients using retrospective data analysis.
- A new predictive score, the Hemorrhagic Transformation Empoli score (HTE), incorporates factors such as NIHSS score, cardioembolic causes, and previous stroke history to assess HT risk.
- The HTE score outperforms five existing prediction scores, showing good predictive power with an AUC of 0.785, indicating its potential for clinical use.
Introduction: Despite Tocilizumab is now recognized as a concrete therapeutic option in patients with severe SARS-CoV-2 related respiratory failure, literature lacks about factors influencing the response to it in this context. Therefore, the aim of our study was to provide evidence about predictors of poor outcome in Tocilizumab treated patients in the real-world practice.
Materials And Methods: We retrospectively analyzed clinical, laboratory and chest computer tomography (CCT) data of patients firstly admitted in non Intensive Care Units (ICU) and suffering from severe respiratory failure, who were treated with the IL-6 antagonist Tocilizumab.